![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NeuroMetrix Initiates Mexican Launch of DPNCheck
NeuroMetrix Initiates Mexican Launch of DPNCheck
![neurometrix.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/neurometrix.gif?t=1626903539&width=430)
December 30, 2015
Medical technology company NeuroMetrix has announced the Mexican launch of its DPNCheck, a quantitative nerve conduction test for the detection of diabetic neuropathy.
The test measures nerve conduction velocity and response amplitude of the sural nerve in the lower leg and ankle, which are recognized as specific biomarkers of DPN.
Nearly 12 percent of the adult population in Mexico has been diagnosed with Type 2 diabetes, and the disease is the leading cause of death in the country with 70,000 fatalities per year, according to NeuroMetrix. — Michael Cipriano
Upcoming Events
-
21Oct